Cargando…

Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)

INTRODUCTION: Intraoperative radiotherapy (IORT) permits accurate delivery of radiation therapy directly to the tumor bed. We report local, regional, and distant recurrence data along with overall and breast cancer-specific survival for 1400 tumors treated with x-ray IORT. METHODS: A total of 1367 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverstein, Melvin J., Epstein, Melinda S., Chen, Peter, Lin, Kevin, Khan, Sadia, Snyder, Lincoln, Coleman, Colleen, Guerra, Lisa, Dehkordi-Vakil, Farideh, Kim, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783657/
https://www.ncbi.nlm.nih.gov/pubmed/35066721
http://dx.doi.org/10.1245/s10434-021-11295-1
_version_ 1784638579835666432
author Silverstein, Melvin J.
Epstein, Melinda S.
Chen, Peter
Lin, Kevin
Khan, Sadia
Snyder, Lincoln
Coleman, Colleen
Guerra, Lisa
Dehkordi-Vakil, Farideh
Kim, Brian
author_facet Silverstein, Melvin J.
Epstein, Melinda S.
Chen, Peter
Lin, Kevin
Khan, Sadia
Snyder, Lincoln
Coleman, Colleen
Guerra, Lisa
Dehkordi-Vakil, Farideh
Kim, Brian
author_sort Silverstein, Melvin J.
collection PubMed
description INTRODUCTION: Intraoperative radiotherapy (IORT) permits accurate delivery of radiation therapy directly to the tumor bed. We report local, regional, and distant recurrence data along with overall and breast cancer-specific survival for 1400 tumors treated with x-ray IORT. METHODS: A total of 1367 patients with 1400 distinct tumors were enrolled in a registry trial. All received breast conservation surgery and low-energy 50 kV x-ray IORT. To be eligible for excision plus IORT as the only local treatment, histopathology had to confirm tumor size ≤30 mm, margins ≥2 mm, negative lymph nodes, and no extensive lymphovascular invasion. Patients who failed any parameters were referred for additional surgery and/or whole breast radiation therapy (WBRT). RESULTS: There were 64 ipsilateral local recurrences, 60 were in the IORT only group, 7 axillary recurrences, and 7 distant recurrences. Forty-one local recurrences were within the same quadrant as the index cancer. Twenty-three were in different quadrants. With 62 months of median follow-up, the 5-year Kaplan–Meier probability of any event for all 1400 tumors was 5.27%. For 1175 patients who received IORT only, it was 5.98%. For favorable subtypes, it ranged from 2.41 to 4.31%. Multivariate analysis revealed that biologic subtype luminal A and the addition of WBRT significantly reduced the risk of local recurrence. CONCLUSIONS: The local, regional, and distant recurrence rates observed were comparable to those reported in the literature for IORT but higher than those reported for standard forms of WBRT, hypofractionated treatment, or APBI. IORT benefits include convenience, decreased exposure to medical environments, and low complication rates.
format Online
Article
Text
id pubmed-8783657
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87836572022-01-24 Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT) Silverstein, Melvin J. Epstein, Melinda S. Chen, Peter Lin, Kevin Khan, Sadia Snyder, Lincoln Coleman, Colleen Guerra, Lisa Dehkordi-Vakil, Farideh Kim, Brian Ann Surg Oncol Breast Oncology INTRODUCTION: Intraoperative radiotherapy (IORT) permits accurate delivery of radiation therapy directly to the tumor bed. We report local, regional, and distant recurrence data along with overall and breast cancer-specific survival for 1400 tumors treated with x-ray IORT. METHODS: A total of 1367 patients with 1400 distinct tumors were enrolled in a registry trial. All received breast conservation surgery and low-energy 50 kV x-ray IORT. To be eligible for excision plus IORT as the only local treatment, histopathology had to confirm tumor size ≤30 mm, margins ≥2 mm, negative lymph nodes, and no extensive lymphovascular invasion. Patients who failed any parameters were referred for additional surgery and/or whole breast radiation therapy (WBRT). RESULTS: There were 64 ipsilateral local recurrences, 60 were in the IORT only group, 7 axillary recurrences, and 7 distant recurrences. Forty-one local recurrences were within the same quadrant as the index cancer. Twenty-three were in different quadrants. With 62 months of median follow-up, the 5-year Kaplan–Meier probability of any event for all 1400 tumors was 5.27%. For 1175 patients who received IORT only, it was 5.98%. For favorable subtypes, it ranged from 2.41 to 4.31%. Multivariate analysis revealed that biologic subtype luminal A and the addition of WBRT significantly reduced the risk of local recurrence. CONCLUSIONS: The local, regional, and distant recurrence rates observed were comparable to those reported in the literature for IORT but higher than those reported for standard forms of WBRT, hypofractionated treatment, or APBI. IORT benefits include convenience, decreased exposure to medical environments, and low complication rates. Springer International Publishing 2022-01-22 2022 /pmc/articles/PMC8783657/ /pubmed/35066721 http://dx.doi.org/10.1245/s10434-021-11295-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Breast Oncology
Silverstein, Melvin J.
Epstein, Melinda S.
Chen, Peter
Lin, Kevin
Khan, Sadia
Snyder, Lincoln
Coleman, Colleen
Guerra, Lisa
Dehkordi-Vakil, Farideh
Kim, Brian
Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)
title Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)
title_full Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)
title_fullStr Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)
title_full_unstemmed Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)
title_short Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)
title_sort recurrence and survival rates for 1400 early breast tumors treated with intraoperative radiation therapy (iort)
topic Breast Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783657/
https://www.ncbi.nlm.nih.gov/pubmed/35066721
http://dx.doi.org/10.1245/s10434-021-11295-1
work_keys_str_mv AT silversteinmelvinj recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT epsteinmelindas recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT chenpeter recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT linkevin recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT khansadia recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT snyderlincoln recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT colemancolleen recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT guerralisa recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT dehkordivakilfarideh recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort
AT kimbrian recurrenceandsurvivalratesfor1400earlybreasttumorstreatedwithintraoperativeradiationtherapyiort